NBTXR3

January 30, 2019January 30, 2019

Nanobiotix Plans Nine NBTXR3 Clinical Trials for Six Cancer Types

News

Nanobiotix is planning to conduct nine Phase 1/2 clinical trials in collaboration with the University of Texas MD Anderson Cancer Center to study the company’s investigational compound NBTXR3. The trials, which will include ... Read more

July 6, 2018

NBTXR3 for Soft Tissue Sarcoma May ‘Change Standard of Care,’ Researcher Says

News

Patients with soft tissue sarcoma who receive NBTXR3 in addition to standard radiation therapy have complete responses twice as often as those receiving radiation therapy alone, a Phase 2/3 clinical trial shows. ... Read more

January 17, 2018January 17, 2018

Providence Cancer Institute, Nanobiotix Partner for Preclinical Study of NBTXR3 in Pancreatic Cancer

News

A preclinical study testing Nanobiotix’s radiotherapy enhancer NBTXR3 in pancreatic cancers is underway as part of a collaboration with one of the world’s leading oncological research centers, the Providence Cancer Institute, ... Read more

January 2, 2018

Nanobiotix Gets FDA Nod to Start Phase 1/2 Trial of NBTXR3 in Head and Neck, Lung Cancers

News

Nanobiotix will soon initiate a Phase 1/2 trial of NBTXR3 in combination with an anti-PD-1 antibody — Bristol-Myers Squibb’s Opdivo (nivolumab) or Merck’s Keytruda (pembrolizumab) — in patients with advanced head and neck ... Read more

October 24, 2017

Last Participants Enrolled in Phase 2/3 Trial of NBTXR3 for Soft Tissue Sarcoma

News

Nanobiotix has completed patient enrollment in its Phase 2/3 trial (Act.In.Sarc), which is evaluating the safety and effectiveness of NBTXR3 in soft tissue sarcoma patients. The last patients are expected to initiate ... Read more

October 4, 2017October 4, 2017

First Clinical Trial Testing NBTXR3 Plus Immune Checkpoint Inhibitors to Recruit Patients in the US

News

The late-clinical-stage company Nanobiotix, which works toward developing new cancer treatment approaches, announced that it will soon launch its first clinical trial with NBTXR3 in combination with immune checkpoint inhibitors ... Read more

June 20, 2017

Radiotherapy Booster NBTXR3 Can Trigger Anti-Tumor Immune Responses, Studies Suggest

News

Nanobiotix’s NBTXR3, a compound designed to increase the efficiency of radiotherapy, also has the ability to make a tumor responsive to immunotherapy, the company reported. A lot of research these ... Read more

May 23, 2017

Nanoparticle Shows Promise in Engaging Immune System to Fight Tumors

News

The radio-enhancer nanoparticle NBTXR3, which is being developed to treat seven types of cancer, can effectively engage patients’ immune systems to fight cancer, transforming “cold” tumors into “hot” tumors. This ... Read more

February 28, 2017

Nanobiotix Appoints New COO to Advance Radio-enhanced Nanoparticle Therapy for Various Cancers

News

Nanobiotix has appointed Alain Dostie, formerly a senior executive with Novartis Germany, as its chief operating officer (COO). Dostie will lead the development, manufacturing, market access, and sales of the company’s lead ... Read more

June 9, 2016June 9, 2016

Preclinical Proof-of-Concept for Cancer Vaccine Announced

News

Nanobiotix has established preliminary preclinical proof-of-concept (POC) with its lead product NBTXR3 for a new program in immuno-oncology (IO). According to the company’s website, Nanobiotix, based in Paris, is “an oncology focused ... Read more